CD73 Inhibitor Compounds Targeting Enzymatic and Non-Enzymatic Functions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer lack effective inhibitors targeting CD73, a key regulatory molecule involved in tumor growth and metastasis, which is overexpressed in various cancers and plays a crucial role in immunosuppression within the tumor microenvironment.
Innovation Solution
Development of specific compounds, represented by Formula (I) and its pharmaceutically acceptable salts, which act as potent inhibitors of CD73, capable of inhibiting its enzymatic activity and interfering with its non-enzymatic functions, thereby potentially halting cancer progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current cancer treatments are used, then existing therapeutic approaches are maintained, but they lack effective inhibitors targeting CD73 which is crucial for controlling tumor growth and metastasis
Solution Approach 1:
The patent segments the CD73 protein into distinct functional domains (enzymatic activity domain and non-enzymatic signaling domain) and develops inhibitors that can selectively target either or both functions. This segmentation allows for tailored therapeutic approaches that address specific pathological mechanisms mediated by CD73.
Solution Approach 2:
The patent employs parameter changes by modifying molecular structures of inhibitor compounds to optimize their binding affinity, selectivity, and pharmacological properties. By systematically varying structural parameters of the inhibitor molecules, the patent achieves enhanced therapeutic effectiveness while minimizing off-target effects.
2Reliability
If CD73 is targeted to inhibit enzymatic activity, then adenosine generation is reduced, but non-enzymatic functions such as cell adhesion and signaling may remain unaffected
Solution Approach 1:
The patent develops dual-function inhibitors that can simultaneously block both the enzymatic activity (AMP hydrolysis) and non-enzymatic functions (cell adhesion, signaling) of CD73. These universal inhibitors address multiple pathological mechanisms through a single therapeutic agent, providing comprehensive coverage of CD73-mediated cancer processes.
Solution Approach 2:
The patent introduces intermediary compounds that bind to specific regions of CD73 to sterically hinder both enzymatic and non-enzymatic interactions. These intermediary inhibitors act as molecular blockers that prevent substrate access to the active site while also interfering with protein-protein interactions required for non-enzymatic functions.
3Adaptability or versatility
If broad-spectrum anti-cancer therapies are used, then multiple cancer pathways are targeted, but specificity for CD73-mediated processes is reduced
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular features that match the unique structural characteristics of the CD73 binding site. By optimizing local interactions at the inhibitor-CD73 interface (hydrogen bonding, hydrophobic interactions, electrostatic contacts), the patent achieves high specificity for CD73 while maintaining potent inhibitory activity.
Solution Approach 2:
The patent employs structure-based drug design by creating inhibitor molecules that replicate key interaction patterns observed in natural CD73 substrates or regulatory proteins. By copying favorable binding motifs and optimizing their pharmacological properties, the patent develops highly specific CD73 inhibitors that mimic beneficial natural interactions while blocking pathological ones.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively target CD73, offering a promising therapeutic approach to control tumor growth and metastasis, serving as both enzymatic and non-enzymatic inhibitors, thus providing a novel strategy for cancer treatment.
Implementation Method 1
CD73 catalyzes the hydrolysis of AMP into adenosine and phosphate... compounds effectively target CD73, offering a promising therapeutic approach to control tumor growth and metastasis, serving as both enzymatic and non-enzymatic inhibitors
Data Source
AI summary
Provided are compounds and methods which may be useful as inhibitors of CD73 for the treatment or prevention of cancer.